Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.

TitleLow-Dose Methotrexate for the Prevention of Atherosclerotic Events.
Publication TypeJournal Article
Year of Publication2019
JournalThe New England journal of medicine
Volume380
Issue8
Pagination752-762
Date Published2019
ISSN0028-4793
Abstract

Inflammation is causally related to atherothrombosis. Treatment with canakinumab, a monoclonal antibody that inhibits inflammation by neutralizing interleukin-1β, resulted in a lower rate of cardiovascular events than placebo in a previous randomized trial. We sought to determine whether an alternative approach to inflammation inhibition with low-dose methotrexate might provide similar benefit.

URLhttp://www.nejm.org/doi/full/10.1056/NEJMoa1809798?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
DOI10.1056/NEJMoa1809798
Short TitleN Engl J Med
X
Enter your linkblue username.
Enter your linkblue password.
Secure Login

This login is SSL protected

Loading